Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
PRNewswire - October 21, 1999
"This filing marks a significant milestone for Nabi in achieving its goal of building a global pharmaceutical business as it is our first foreign application for a finished pharmaceutical product", stated David J. Gury, Chairman and CEO of Nabi.
Hepatitis B is the most severe form of viral hepatitis and the leading cause of liver cancer. One hundred times more infectious than the AIDS virus, it is the ninth leading cause of death worldwide. It is estimated that 350 million people worldwide are chronically infected with the hepatitis B virus (HBV), one-third of whom are expected to develop serious liver disease, and approximately 1 million will die each year. At-risk individuals include healthcare workers, neonates born to HBV-positive mothers and sexually active individuals with multiple partners.
Nabi, a fully integrated biopharmaceutical company, has a broad product portfolio and significant R&D capabilities focused on the development and commercialization of drugs that prevent and treat infectious and autoimmune diseases. Nabi currently has several clinical trials underway in these areas and has four marketed pharmaceutical products. Additional information may be obtained on the Company's website at http://www.nabi.com .
This press release may contain forward-looking statements that reflect the Company's current expectations regarding future events. While these statements reflect the Company's best current judgment, they are subject to risks and uncertainties. Actual results may differ significantly from the results projected herein due to a number of factors, including, but not limited to, the impact on the Company of current industry supply and demand factors and the supply of and demand for the Company's individual products; margin pressure on the Company's non-specific antibody product line; future sales growth prospects for its pharmaceutical products; the likelihood that any product in the research pipeline can receive regulatory approval in the U.S. or abroad or be successfully developed, manufactured and marketed; failure to receive licensure for the Boca Raton manufacturing facility; and dependence upon third parties to manufacture product. These factors are more fully discussed in the Company's most recent Form 10-K filed with the Securities and Exchange Commission.
SOURCE Nabi
CONTACT: Tanina Frouge, Director, Investor Relations, 561-989-5815, for Nabi/
Web Site: /http://www.nabi.com /
991021
PR991045
Copyright © 1999 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .